Fig. 3
From: NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer
Representative image of 231Br brain metastases (a) and corresponding 14C-Irinotecan accumulation (b) in metastases 2 h after intravenous administration of radiolabeled irinotecan. Representative image of 231Br brain metastases (c) and corresponding 14C-NKTR-102 accumulation (d) in metastases 6 h after intravenous administration of radiolabeled NKTR-102. 14C-irinotecan concentration versus 231Br lesion size in individual metastases (e). 14C-NKTR-102 concentration versus 231Br lesion size in individual metastases (f). Dashed line in panel (e) and f represents mean BDT 14CIrinotecan and 14C-NKTR-102 concentration respectively. Mean BDT and lesion accumulation of 14C-Irinotecan (white columns) and 14C-NKTR-102 (black columns) (g). Mean lesion accumulations of 14C-Irinotecan and 14C-NKTR-102 were significantly different. All data are Mean ± SEM (n = 8-10)